Research ExplorerPublicationsNatriuretic peptides and panic disorder

Natriuretic peptides and panic disorder

Standard

Natriuretic peptides and panic disorder : therapeutic prospects. / Kellner, Michael; Jahn, Holger; Wiedemann, Klaus.

In: EXPERT REV NEUROTHER, Vol. 3, No. 3, 05.2003, p. 381-6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kellner, M, Jahn, H & Wiedemann, K 2003, 'Natriuretic peptides and panic disorder: therapeutic prospects', EXPERT REV NEUROTHER, vol. 3, no. 3, pp. 381-6. https://doi.org/10.1586/14737175.3.3.381

APA

Kellner, M., Jahn, H., & Wiedemann, K. (2003). Natriuretic peptides and panic disorder: therapeutic prospects. EXPERT REV NEUROTHER, 3(3), 381-6. https://doi.org/10.1586/14737175.3.3.381

Vancouver

Kellner M, Jahn H, Wiedemann K. Natriuretic peptides and panic disorder: therapeutic prospects. EXPERT REV NEUROTHER. 2003 May;3(3):381-6. https://doi.org/10.1586/14737175.3.3.381

Bibtex

@article{2c5acf24c2cc44d1a7e9cd321037bda0,
title = "Natriuretic peptides and panic disorder: therapeutic prospects",
abstract = "Natriuretic peptides differentially modulate endocrine and behavioral stress responses in preclinical and human studies. While atrial natriuretic peptide inhibits the hypothalamic-pituitary-adrenocortical axis, C-type natriuretic peptide exerts stimulatory activity. In rodents, atrial natriuretic peptide reduces anxiety, whereas C-type natriuretic peptide has anxiogenic effects (mediated via corticotropin-releasing hormone). Patients with panic disorder show lower basal ANP plasma levels but a more pronounced release during experimentally induced panic attacks compared with controls. This could explain the absent pituitary-adrenocortical activation during panic anxiety and its paroxysmal nature. Furthermore, the effects of the panicogen cholecystokinin-tetrapeptide are attenuated by ANP pretreatment in panic patients, while C-type natriuretic peptide demonstrates anxiogenic action in healthy humans. Atrial natriuretic peptide agonists and C-type natriuretic peptide antagonists may have potential as a new class of antipanic and anxiolytic psychotherapeutic medication.",
author = "Michael Kellner and Holger Jahn and Klaus Wiedemann",
year = "2003",
month = may,
doi = "10.1586/14737175.3.3.381",
language = "English",
volume = "3",
pages = "381--6",
journal = "EXPERT REV NEUROTHER",
issn = "1473-7175",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

RIS

TY - JOUR

T1 - Natriuretic peptides and panic disorder

T2 - therapeutic prospects

AU - Kellner, Michael

AU - Jahn, Holger

AU - Wiedemann, Klaus

PY - 2003/5

Y1 - 2003/5

N2 - Natriuretic peptides differentially modulate endocrine and behavioral stress responses in preclinical and human studies. While atrial natriuretic peptide inhibits the hypothalamic-pituitary-adrenocortical axis, C-type natriuretic peptide exerts stimulatory activity. In rodents, atrial natriuretic peptide reduces anxiety, whereas C-type natriuretic peptide has anxiogenic effects (mediated via corticotropin-releasing hormone). Patients with panic disorder show lower basal ANP plasma levels but a more pronounced release during experimentally induced panic attacks compared with controls. This could explain the absent pituitary-adrenocortical activation during panic anxiety and its paroxysmal nature. Furthermore, the effects of the panicogen cholecystokinin-tetrapeptide are attenuated by ANP pretreatment in panic patients, while C-type natriuretic peptide demonstrates anxiogenic action in healthy humans. Atrial natriuretic peptide agonists and C-type natriuretic peptide antagonists may have potential as a new class of antipanic and anxiolytic psychotherapeutic medication.

AB - Natriuretic peptides differentially modulate endocrine and behavioral stress responses in preclinical and human studies. While atrial natriuretic peptide inhibits the hypothalamic-pituitary-adrenocortical axis, C-type natriuretic peptide exerts stimulatory activity. In rodents, atrial natriuretic peptide reduces anxiety, whereas C-type natriuretic peptide has anxiogenic effects (mediated via corticotropin-releasing hormone). Patients with panic disorder show lower basal ANP plasma levels but a more pronounced release during experimentally induced panic attacks compared with controls. This could explain the absent pituitary-adrenocortical activation during panic anxiety and its paroxysmal nature. Furthermore, the effects of the panicogen cholecystokinin-tetrapeptide are attenuated by ANP pretreatment in panic patients, while C-type natriuretic peptide demonstrates anxiogenic action in healthy humans. Atrial natriuretic peptide agonists and C-type natriuretic peptide antagonists may have potential as a new class of antipanic and anxiolytic psychotherapeutic medication.

U2 - 10.1586/14737175.3.3.381

DO - 10.1586/14737175.3.3.381

M3 - SCORING: Journal article

C2 - 19810905

VL - 3

SP - 381

EP - 386

JO - EXPERT REV NEUROTHER

JF - EXPERT REV NEUROTHER

SN - 1473-7175

IS - 3

ER -